Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric A Hughes

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Immunity|March 26, 2002
Immune response to Salmonella: location, location, location?Eric A Hughes, Jorge E Galán
Journal of Clinical and Translational Science|October 31, 2024
Overview of ACTIV trial-specific lessons learnedRuxandra Draghia-Akli, Sarah W Read, Eric A Hughes
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 19, 2012
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantationRobert J Fontana, Eric A Hughes, Henry Appelman, et al.
Clinical Pharmacokinetics|July 18, 2012
Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal functionMichelle Treitel, Thomas Marbury, Richard A Preston, et al.
Annals of Internal Medicine|June 28, 2021
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 TherapeuticsLisa LaVange, Stacey J Adam, Judith S Currier, et al.
Hepatology (Baltimore, Md.)|January 13, 2016
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrenceFred Poordad, Eugene R Schiff, John M Vierling, et al.
Antiviral Therapy|January 24, 2014
A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infectionFumitaka Suzuki, Joji Toyota, Kenji Ikeda, et al.
Antiviral Therapy|January 24, 2014
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1Namiki Izumi, Osamu Yokosuka, Norifumi Kawada, et al.
Critical Care Medicine|September 8, 2021
Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical TrialsTimothy G Buchman, Ruxandra Draghia-Akli, Stacey J Adam, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 13, 2016
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)Mark S Sulkowski, Steve Flamm, Zeid Kayali, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Immunity|March 26, 2002
Immune response to Salmonella: location, location, location?Eric A Hughes, Jorge E Galán
Journal of Clinical and Translational Science|October 31, 2024
Overview of ACTIV trial-specific lessons learnedRuxandra Draghia-Akli, Sarah W Read, Eric A Hughes
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 19, 2012
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantationRobert J Fontana, Eric A Hughes, Henry Appelman, et al.
Clinical Pharmacokinetics|July 18, 2012
Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal functionMichelle Treitel, Thomas Marbury, Richard A Preston, et al.
Annals of Internal Medicine|June 28, 2021
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 TherapeuticsLisa LaVange, Stacey J Adam, Judith S Currier, et al.
Hepatology (Baltimore, Md.)|January 13, 2016
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrenceFred Poordad, Eugene R Schiff, John M Vierling, et al.
Antiviral Therapy|January 24, 2014
A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infectionFumitaka Suzuki, Joji Toyota, Kenji Ikeda, et al.
Antiviral Therapy|January 24, 2014
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1Namiki Izumi, Osamu Yokosuka, Norifumi Kawada, et al.
Critical Care Medicine|September 8, 2021
Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical TrialsTimothy G Buchman, Ruxandra Draghia-Akli, Stacey J Adam, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 13, 2016
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)Mark S Sulkowski, Steve Flamm, Zeid Kayali, et al.
Pageof 3